Loading
A phase 1/2 trial of Pomalidomide, Dexamethasone, Azacitidine in hodgkin lymphoma and non-hodgkin lymphoma, run by CellCentric Ltd., now recruiting.
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies is a phase 1/2 interventional study registered as NCT04068597 by CellCentric Ltd., with 250 participants planned, started 2019-08-09 and due to reach its primary completion in 2027-03-31. Interventions recorded: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax. Conditions listed: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Venetoclax, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/